CH-223191 [301326-22-7]
Référence T2448-5mg
Conditionnement : 5mg
Marque : TargetMol
CH-223191
(Synonyms: CH 223191) Copy Product Info
CH-223191 is a specific and effective aromatic hydrocarbon receptor (AhR) antagonist, and its IC50 value for inhibiting luciferase activity induced by TCDD is 0.03 μM. CH-223191 can be used in tumor immunotherapy, cytotoxicity research, stem cell research, inflammation research and neuroprotection.
Cas No. 301326-22-7
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.87%
Color:Yellow to Orange
COA LCMS
Product Information
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | CH-223191 is a specific and effective aromatic hydrocarbon receptor (AhR) antagonist, and its IC50 value for inhibiting luciferase activity induced by TCDD is 0.03 μM. CH-223191 can be used in tumor immunotherapy, cytotoxicity research, stem cell research, inflammation research and neuroprotection. |
| Targets & IC50 | AhR:30 nM |
| In vitro | METHODS: HepG2 cells were treated with CH-223191 (0.1-10 μM) for 1 hour, and the protein levels were detected by Western Blot method. RESULTS: C-223191 reduces the expression of cytochrome P450 1A1 protein caused by TCDD. [1] |
| In vivo | METHODS: To study the preventive toxic effects of CH-223191 on 2,3,7,8-TCDD, CH-223191 (10 mg/kg) was intraperitoneally injected into male ICR mice once a day for 25 consecutive days. RESULTS: C-223191 inhibited the expression of liver cytochrome P450 1A1 and the intracellular fat content in hepatocytes, and reduced the AST and ALT activities in mice treated with TCDD. [1] |
| Synonyms | CH 223191 |
| Molecular Weight | 333.39 |
| Formula | C19H19N5O |
| Cas No. | 301326-22-7 |
| Smiles | Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1 |
| Relative Density. | 1.20 g/cm3 (Predicted) |
| Storage | The compound is unstable in solution. Please use soon, Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 3.3 mg/mL (9.9 mM), Sonication is recommended. DMSO: 127 mg/mL (380.94 mM), Sonication is recommended.  | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1 mg/mL (3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||